CL2021001665A1 - Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos. - Google Patents

Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos.

Info

Publication number
CL2021001665A1
CL2021001665A1 CL2021001665A CL2021001665A CL2021001665A1 CL 2021001665 A1 CL2021001665 A1 CL 2021001665A1 CL 2021001665 A CL2021001665 A CL 2021001665A CL 2021001665 A CL2021001665 A CL 2021001665A CL 2021001665 A1 CL2021001665 A1 CL 2021001665A1
Authority
CL
Chile
Prior art keywords
compositions
methods
aminophenyl
piperidine
amino
Prior art date
Application number
CL2021001665A
Other languages
English (en)
Inventor
Joshua Hansen
Matthew D Correa
Timothy S Kercher
Mark A Nagy
Brandon W Whitefield
Veronique Plantevin-Krenitsky
Massimo Ammirante
Sogoie Bahmanyar
Virginia Grant
Evan J Horn
Christopher Mayne
Rama Krishna Narla
Surendra Nayak
Stephen Norris
Patrick Papa
John J Sapienza
Shuichan Su
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2021001665A1 publication Critical patent/CL2021001665A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En la presente se proporcionan compuestos de piperidindiona que tienen la siguiente estructura (I); en donde RN, R1, R2, R3, R4, L, V, m y n son, como se definen en la presente, composiciones que comprenden una cantidad eficaz de un compuesto de piperidindiona, y métodos para tratar o prevenir una enfermedad mediada por el receptor androgénico.
CL2021001665A 2018-12-19 2021-06-18 Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos. CL2021001665A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862782298P 2018-12-19 2018-12-19
US201962879900P 2019-07-29 2019-07-29

Publications (1)

Publication Number Publication Date
CL2021001665A1 true CL2021001665A1 (es) 2022-01-14

Family

ID=71098067

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001665A CL2021001665A1 (es) 2018-12-19 2021-06-18 Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos.

Country Status (29)

Country Link
US (3) US11149007B2 (es)
EP (2) EP4494711A3 (es)
JP (2) JP7494181B2 (es)
KR (2) KR102866144B1 (es)
CN (2) CN113453681B (es)
AU (1) AU2019403207B2 (es)
BR (1) BR112021011968A2 (es)
CA (1) CA3124130A1 (es)
CL (1) CL2021001665A1 (es)
CO (1) CO2021007973A2 (es)
DK (1) DK3897636T3 (es)
ES (1) ES3009308T3 (es)
FI (1) FI3897636T3 (es)
HR (1) HRP20250095T1 (es)
HU (1) HUE070506T2 (es)
IL (1) IL284223B2 (es)
LT (1) LT3897636T (es)
MX (1) MX2021007473A (es)
MY (1) MY205718A (es)
PE (1) PE20212247A1 (es)
PL (1) PL3897636T3 (es)
PT (1) PT3897636T (es)
RS (1) RS66556B1 (es)
SG (1) SG11202106507RA (es)
SI (1) SI3897636T1 (es)
SM (1) SMT202500111T1 (es)
TW (1) TWI820276B (es)
WO (1) WO2020132014A1 (es)
ZA (1) ZA202104200B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
CN113453681B (zh) * 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
KR20230027066A (ko) * 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
JP7778095B2 (ja) * 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
AU2021311245A1 (en) * 2020-07-21 2023-03-09 Ubix Therapeutics, Inc. Compound for androgen receptor degradation, and pharmaceutical use thereof
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN117203196A (zh) 2020-12-14 2023-12-08 拜欧斯瑞克斯公司 Pde4降解剂、药物组合物和治疗应用
BR112023018839A2 (pt) * 2021-03-17 2023-12-26 Medshine Discovery Inc Composto de glutarimida substituído por anel fundido com furano
KR20240026946A (ko) * 2021-06-25 2024-02-29 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
WO2022272061A1 (en) * 2021-06-25 2022-12-29 Celgene Corporation Cereblon binding compounds, compositions thereof, and methods of treatment therewith
CN117561249A (zh) * 2021-06-25 2024-02-13 细胞基因公司 Cereblon结合化合物、其组合物及其用于治疗的方法
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
CN120152718A (zh) * 2022-11-09 2025-06-13 百时美施贵宝公司 用取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物的组合疗法
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮
WO2025235600A1 (en) * 2024-05-07 2025-11-13 Bristol-Myers Squibb Company Processes for the preparation of substituted 3-((3-aminophenyl)amino) piperidine-2,6-dione compounds
WO2025235577A1 (en) 2024-05-09 2025-11-13 Bristol-Myers Squibb Company Forms and formulations of substituted 3-((3-amino)piperidine-2,6-dione compounds
CN118993935B (zh) * 2024-10-23 2025-02-14 江苏恒瑞医药股份有限公司 咪唑啉衍生物或其盐的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302485A1 (de) 1993-01-29 1994-08-04 Merck Patent Gmbh Piperazinderivate
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
FR2768728B1 (fr) 1997-09-19 1999-12-03 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique
FR2768729A1 (fr) 1997-09-19 1999-03-26 Rhodia Chimie Sa Procede d'acylation d'un compose aromatique et complexes catalytiques
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US8470829B2 (en) * 2004-09-09 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Imidazolidine derivative and use thereof
WO2007073432A2 (en) 2005-10-11 2007-06-28 Chemocentryx, Inc. Piperidine derivatives and methods of use
US20080064876A1 (en) * 2006-05-16 2008-03-13 Muller George W Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
EP2683694B1 (en) * 2011-03-10 2016-04-27 Suzhou Kintor Pharmaceuticals, Inc. Androgen receptor antagonists and uses thereof
US20140112922A1 (en) 2011-03-28 2014-04-24 Cornell University Targeted protein silencing using chimeras between antibodies and ubiquitination enzymes
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
WO2014036897A1 (zh) * 2012-09-04 2014-03-13 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
RU2683788C2 (ru) 2013-01-31 2019-04-02 Вертекс Фармасьютикалз Инкорпорейтед Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2557235C1 (ru) * 2014-07-08 2015-07-20 Александр Васильевич Иващенко Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3319944A4 (en) 2015-07-10 2019-04-24 Arvinas, Inc. MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
CN110167556A (zh) 2016-07-08 2019-08-23 詹森药业有限公司 用于治疗癌症的硫代乙内酰脲雄性激素受体拮抗剂
TWI739888B (zh) 2016-10-07 2021-09-21 美商陶氏農業科學公司 農藥組合物及方法
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
US10925868B2 (en) 2016-11-10 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
WO2018098280A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
AU2017378943B2 (en) 2016-12-19 2020-06-18 Abbisko Therapeutics Co., Ltd. FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
CN109422725A (zh) 2017-09-04 2019-03-05 北京美倍他药物研究有限公司 前列腺癌治疗药物
ES2959954T3 (es) 2017-11-28 2024-02-29 Aarti Pharmalabs Ltd Proceso para la preparación de enzalutamida utilizando un nuevo intermedio
EP3720281A4 (en) 2017-12-05 2021-05-26 Dow Agrosciences LLC PESTICIDE COMPOSITIONS AND PROCEDURES
CN114835729B (zh) 2018-05-30 2024-05-31 江苏豪森药业集团有限公司 含三并环类衍生物抑制剂、其制备方法和应用
CN109651256A (zh) 2018-11-20 2019-04-19 上海健康医学院 一种式（viii）的恩杂鲁胺的制备方法
CN113453681B (zh) * 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法

Also Published As

Publication number Publication date
CN119219606A (zh) 2024-12-31
EP4494711A3 (en) 2025-05-21
US20200199073A1 (en) 2020-06-25
TWI820276B (zh) 2023-11-01
WO2020132014A1 (en) 2020-06-25
TW202039435A (zh) 2020-11-01
PL3897636T3 (pl) 2025-04-28
JP7724911B2 (ja) 2025-08-18
CN113453681B (zh) 2024-10-11
KR20250144505A (ko) 2025-10-10
CN113453681A (zh) 2021-09-28
IL284223B2 (en) 2025-08-01
JP2022514344A (ja) 2022-02-10
CA3124130A1 (en) 2020-06-25
SG11202106507RA (en) 2021-07-29
MY205718A (en) 2024-11-07
KR102866144B1 (ko) 2025-09-30
HRP20250095T1 (hr) 2025-04-11
NZ777281A (en) 2025-07-25
HUE070506T2 (hu) 2025-06-28
JP2024109765A (ja) 2024-08-14
ES3009308T3 (en) 2025-03-26
SI3897636T1 (sl) 2025-04-30
PE20212247A1 (es) 2021-11-24
LT3897636T (lt) 2025-03-25
MX2021007473A (es) 2021-08-05
US11873283B2 (en) 2024-01-16
BR112021011968A2 (pt) 2021-09-08
FI3897636T3 (fi) 2025-02-03
US20240368083A1 (en) 2024-11-07
EP3897636A1 (en) 2021-10-27
EP3897636B1 (en) 2024-12-11
DK3897636T3 (da) 2025-01-13
PT3897636T (pt) 2025-01-27
US20230002321A1 (en) 2023-01-05
US11149007B2 (en) 2021-10-19
EP3897636A4 (en) 2022-09-07
RS66556B1 (sr) 2025-03-31
SMT202500111T1 (it) 2025-05-12
US12404241B2 (en) 2025-09-02
IL284223A (en) 2021-08-31
JP7494181B2 (ja) 2024-06-03
AU2019403207A1 (en) 2021-07-15
EP4494711A2 (en) 2025-01-22
CO2021007973A2 (es) 2021-09-09
ZA202104200B (en) 2024-11-27
KR20210118816A (ko) 2021-10-01
IL284223B1 (en) 2025-04-01
AU2019403207B2 (en) 2025-06-05

Similar Documents

Publication Publication Date Title
CL2021001665A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos.
CO2022018653A2 (es) Compuestos de unión a cereblón, composiciones de estos y métodos de tratamiento con estos
MX2021007475A (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos.
CL2021003134A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
CO2020012824A2 (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma
DOP2019000110A (es) 1,2,4–triazolonas 2,4,5–trisustituidas
MX389798B (es) Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
PE20180508A1 (es) Amidas heterociclicas como inhibidores de quinasa
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
MX2022001764A (es) Composiciones que comprenden tigolaner para el control de parasitos.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
CL2020001107A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
CO2022000186A2 (es) Nuevos compuestos heterocíclicos
UY38397A (es) Nuevos oxadiazoles
ECSP056011A (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol
UY29197A1 (es) Compuestos de n-sulfonilaminobencil-2-fenoxiacetamida sustituidos
CR20110305A (es) Péptidos antagonistas de crhr2 y usos de estos
AR053339A1 (es) Composiciones para el tratamiento del cabello y/o del cuero cabelludo
UY28925A1 (es) Nuevos derivados de aminopiridina y su uso como fármacos
EA202191712A1 (ru) Соединения замещенного 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью
MX2020003554A (es) Moduladores de la expresion de enac.
EA202191713A1 (ru) Замещенные соединения 3-((3-аминофенил)амино)пиперидин-2,6-диона, их композиции и способы лечения с их помощью